Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumours - Issei Achiwa; Hironobu Minami; Masato Takahashi; J. Watanabe; Yunjoo Im; Yasuyuki Okuda; Ichiro Kinoshita; Noboru Yamamoto; Emi Kamiyama; Satoshi Takahashi; T. Fujiki; Caleb Lee; et al. (Annals of Oncology, 2019)